Artal Group S.A. Solid Biosciences Inc. Transaction History

Artal Group S.A.

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2021 Nov 12, 2021	BUY	$2.38 - $3.77 $1.79 Million - $2.83 Million	750,000 Added 33.33%	3,000,000 $7.17 Million
Q1 2021 May 14, 2021	BUY	$5.37 - $10.72 $12.1 Million - $24.1 Million	2,250,000 New	2,250,000 $12.4 Million
Q4 2020 Feb 11, 2021	SELL	$3.08 - $7.79 $5.27 Million - $13.3 Million	-1,710,000 Closed	0 $0
Q3 2020 Nov 13, 2020	SELL	$2.02 - $3.08 $181,800 - $277,200	-90,000 Reduced 5.0%	1,710,000 $3.47 Million
Q4 2019 Feb 13, 2020	BUY	$2.82 - $12.9 $282,000 - $1.29 Million	100,000 Added 5.88%	1,800,000 $8.01 Million
Q3 2019 Nov 14, 2019	BUY	$4.33 - $11.64 $2.17 Million - $5.82 Million	500,000 Added 41.67%	1,700,000 $17.6 Million
Q1 2019 May 10, 2019	BUY	$7.19 - $32.37 $5.03 Million - $22.7 Million	700,000 Added 140.0%	1,200,000 $11 Million
Q4 2018 Feb 11, 2019	BUY	$21.32 - $46.34 $5.86 Million - $12.7 Million	275,000 Added 122.22%	500,000 $13.4 Million
Q3 2018 Nov 09, 2018	SELL	$36.35 - $51.7 $908,750 - $1.29 Million	-25,000 Reduced 10.0%	225,000 $10.6 Million
Q2 2018 Aug 10, 2018	BUY	$7.33 - $43.15 $733,000 - $4.32 Million	100,000 Added 66.67%	250,000 $8.91 Million
Q1 2018 May 10, 2018	BUY	$7.19 - $33.17 $1.08 Million - $4.98 Million	150,000 New	150,000 $1.13 Million

Ticker SLDB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 7,533,080
Market Cap $29.8M
Description
Solid Biosciences Inc. engages in developing therapies for duchenne muscular dystrophy in the United States. The company's lead product candidate is SGT-001, a gene transfer candidate, which is in a Phase I/II clinical trial to drive functional dystrophin protein expression in patients' muscles; and SGT-003, a ext-generation gene transfer candid...

Get notified when there are updates to the investment portfolio of Artal Group S.A., based on Form 13F filings with the SEC.

Stay updated on Artal Group S.A. with notifications on news.